Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib

Fig. 5

Gilteritinib upregulated the expression of NKG2DLs and FLT3 in AML cells from patients with FLT3mut+ and FLT3mut− AML and in the bone marrow of xenograft mouse models. A-B Flow cytometry analysis indicated that NKG2DL expression in AML cells from patients with FLT3mut+ or FLT3mut− AML was significantly elevated with gilteritinib treatment. Histograms show NKG2DL expression on FLT3mut+ or FLT3mut− AML in the absence (grey) and presence (black) of gilteritinib for 24 h. Inset numbers showed the ratio in MFI of treated/non-treated cells. C The upregulation of FLT3 following gilteritinib treatment was only detected in cells from patients with FLT3mut+ AML and not in cells from patients with FLT3mut− AML. Histograms show FLT3 expression on FLT3mut+ or FLT3mut− AML in the absence (grey) and presence (black) of gilteritinib for 24 h. Inset numbers showed the ratio in MFI of treated/non-treated cells. D In xenograft models, bone marrow immunofluorescence staining showed the density of NKG2DL ULBP1 and FLT3 cells. E The diagram showed the MFIs of NKG2DL ULBP1 (green) and FLT3 (red) measured by ImageJ from n = 3 mice in each group. G, gilteritinib; MFI, mean fluorescence intensity. ns, not significant. * p < 0.05; ** p < 0.01; *** p < 0.001

Back to article page

Molecular Cancer

ISSN: 1476-4598